Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies

1.

Thwaites GE, Day NP. Approach to fever in the returning traveler. N Engl J Med. 2017;376(6):548–60. doi:10.1056/NEJMra1508435.PubMedCrossRef

2.

Redshaw CH, Stahl-Timmins WM, Fleming LE, Davidson I, Depledge MH. Potential changes in disease patterns and pharmaceutical use in response to climate change. J Toxicol Environ Health B Crit Rev. 2013;16(5):285–320. doi:10.1080/10937404.2013.802265.PubMedPubMedCentralCrossRef

3.

Pachauri R, Meyer L. Climate Change 2014: Synthesis Report. Contribution of Working Groups I, II and III to the Fifth Assessment Report of the Intergovernmental Panel on Climate Change. Geneva2014.

4.

Beugnet F, Chalvet-Monfray K. Impact of climate change in the epidemiology of vector-borne diseases in domestic carnivores. Comp Immunol Microbiol Infect Dis. 2013;36(6):559–66. doi:10.1016/j.cimid.2013.07.003.PubMedCrossRef

5.

Wu X, Lu Y, Zhou S, Chen L, Xu B. Impact of climate change on human infectious diseases: empirical evidence and human adaptation. Environ Int. 2016;86:14–23. doi:10.1016/j.envint.2015.09.007.PubMedCrossRef

6.

Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367(23):2214–25. doi:10.1056/NEJMoa1204781.PubMedCrossRef

7.

Patz JA, Olson SH. Climate change and health: global to local influences on disease risk. Ann Trop Med Parasitol. 2006;100(5–6):535–49. doi:10.1179/136485906X97426.PubMedCrossRef

8.

Reiter P. Climate change and mosquito-borne disease. Environ Health Perspect. 2001;109(Suppl 1):141–61.PubMedPubMedCentralCrossRef

9.

Gilbert L, Aungier J, Tomkins JL. Climate of origin affects tick (Ixodes ricinus) host-seeking behavior in response to temperature: implications for resilience to climate change? Ecol Evol. 2014;4(7):1186–98. doi:10.1002/ece3.1014.PubMedPubMedCentralCrossRef

10.

Kilpatrick AM, Randolph SE. Drivers, dynamics, and control of emerging vector-borne zoonotic diseases. Lancet. 2012;380(9857):1946–55. doi:10.1016/S0140-6736(12)61151-9.PubMedPubMedCentralCrossRef

11.

Farmer P. Social inequalities and emerging infectious diseases. Emerg Infect Dis. 1996;2(4):259–69. doi:10.3201/eid0204.960402.PubMedPubMedCentralCrossRef

12.

Ordman CW, Jennings CG, Janeway CA. Chemical, clinical, and immunological studies on the products of human plasma fractionation. Xii. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prevention and attenuation of measles. J Clin Invest. 1944;23(4):541–9. doi:10.1172/JCI101519.PubMedPubMedCentralCrossRef

13.

Krugman S, Ward R, Giles JP. The natural history of infectious hepatitis. Am J Med. 1962;32:717–28.PubMedCrossRef

14.

Fischer GW, Hunter KW, Hemming VG, Wilson SR. Functional antibacterial activity of a human intravenous immunoglobulin preparation: in vitro and in vivo studies. Vox Sang. 1983;44(5):296–9.PubMedCrossRef

15.

Hemming VG, Fischer GW, Prince GA. Giant cell pneumonia due to respiratory syncytial virus. Arch Pathol Lab Med. 1985;109(3):213.PubMed

16.

Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol. 2001;101(3):284–8. doi:10.1006/clim.2001.5132.PubMedCrossRef

17.

Girmenia C, Serrao A, Canichella M. Epidemiology of Carbapenem resistant Klebsiella pneumoniae infections in Mediterranean countries. Mediterr J Hematol Infect Dis. 2016;8(1):e2016032. doi:10.4084/MJHID.2016.032.PubMedPubMedCentralCrossRef

18.

Planitzer CB, Modrof J, Kreil TR. West Nile virus neutralization by US plasma-derived immunoglobulin products. J Infect Dis. 2007;196(3):435–40. doi:10.1086/519392.PubMedCrossRef

19.

Papadopoulou-Alataki E, Hassan A, Davies EG. Prevention of infection in children and adolescents with primary immunodeficiency disorders. Asian Pac J Allergy Immunol. 2012;30(4):249–58.PubMed

20.

Medical Advisory Committee of the Immune Deficiency F, Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133(4):961–6. doi:10.1016/j.jaci.2013.11.043.CrossRef

21.

Doherty M, Schmidt-Ott R, Santos JI, Stanberry LR, Hofstetter AM, Rosenthal SL, et al. Vaccination of special populations: protecting the vulnerable. Vaccine. 2016;34(52):6681–90. doi:10.1016/j.vaccine.2016.11.015.PubMedCrossRef

22.

Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4(6):1066–75. doi:10.1016/j.jaip.2016.09.012.PubMedCrossRef

23.

Ariza-Heredia EJ, Gulbis AM, Stolar KR, Kebriaei P, Shah DP, McConn KK, et al. Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis. 2014;16(6):878–86. doi:10.1111/tid.12312.PubMedCrossRef

24.

Martin J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals. 2006;34(2):117–22. doi:10.1016/j.biologicals.2006.02.005.PubMedCrossRef

25.

Marciano BE, Huang CY, Joshi G, Rezaei N, Carvalho BC, Allwood Z, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133(4):1134–41. doi:10.1016/j.jaci.2014.02.028.PubMedPubMedCentralCrossRef

26.

Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, et al. Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Clin Microbiol Infect. 2014;20(10):O656–63. doi:10.1111/1469-0691.12573.PubMedCrossRef

27.

Neven B, Perot P, Bruneau J, Pasquet M, Ramirez M, Diana JS, et al. Cutaneous and visceral chronic granulomatous disease triggered by a rubella virus vaccine strain in children with primary immunodeficiencies. Clin Infect Dis. 2017;64(1):83–6. doi:10.1093/cid/ciw675.PubMedCrossRef

28.

Perelygina L, Plotkin S, Russo P, Hautala T, Bonilla F, Ochs HD, et al. Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2016;138(5):1436–1439 e11. doi:10.1016/j.jaci.2016.06.030.PubMedPubMedCentralCrossRef

29.

Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine. 2014;32(30):3725–31. doi:10.1016/j.vaccine.2014.05.022.PubMedCrossRef

30.

Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne JP. Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. Biomed Res Int. 2014;2014:305784. doi:10.1155/2014/305784.PubMedPubMedCentralCrossRef

31.

Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int. 2014;2014:249856. doi:10.1155/2014/249856.PubMedPubMedCentralCrossRef

32.

Chen S, Hu F, Zhang X, Xu X, Liu Y, Zhu D, et al. Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatment. J Clin Microbiol. 2011;49(11):4022–3. doi:10.1128/JCM.01233-11.PubMedPubMedCentralCrossRef

33.

Rath S, Panda M, Sahu MC, Padhy RN. Bayesian analysis of two diagnostic methods for paediatric ringworm infections in a teaching hospital. J Mycol Med. 2015;25(3):191–9. doi:10.1016/j.mycmed.2015.06.065.PubMedCrossRef

34.

Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis. 2012;2012:976273. doi:10.1155/2012/976273.PubMedPubMedCentralCrossRef

35.

Monaco M, Pimentel de Araujo F, Cruciani M, Coccia EM, Pantosti A. Worldwide epidemiology and antibiotic resistance of Staphylococcus aureus. Curr Top Microbiol Immunol. 2016; doi:10.1007/82_2016_3.

36.

Kamboj M, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant. 2010;16(11):1576–81. doi:10.1016/j.bbmt.2010.05.008.PubMedPubMedCentralCrossRef

37.

Workowski KA, Bolan GA, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1–137.PubMed

38.

Bignell C, Unemo M, European STIGEB. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24(2):85–92. doi:10.1177/0956462412472837.PubMedCrossRef

39.

Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med. 2012;366(6):485–7. doi:10.1056/NEJMp1112456.PubMedCrossRef

40.

WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2016.

41.

Segal BH. Aspergillosis. N Engl J Med. 2009;360(18):1870–84. doi:10.1056/NEJMra0808853.PubMedCrossRef

42.

Lionakis MS, Netea MG, Holland SM. Mendelian genetics of human susceptibility to fungal infection. Cold Spring Harb Perspect Med. 2014;4(6). doi:10.1101/cshperspect.a019638.

43.

Lanternier F, Cypowyj S, Picard C, Bustamante J, Lortholary O, Casanova JL, et al. Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr. 2013;25(6):736–47. doi:10.1097/MOP.0000000000000031.PubMedPubMedCentral

44.

Rieber N, Gazendam RP, Freeman AF, Hsu AP, Collar AL, Sugui JA, et al. Extrapulmonary Aspergillus infection in patients with CARD9 deficiency. JCI Insight. 2016;1(17):e89890. doi:10.1172/jci.insight.89890.PubMedPubMedCentralCrossRef

45.

Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15. doi:10.1056/NEJMoa020191.PubMedCrossRef

46.

Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother. 2012;56(1):10–6. doi:10.1128/AAC.05088-11.PubMedPubMedCentralCrossRef

47.

Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362–8. doi:10.1093/cid/civ885.PubMedCrossRef

48.

Verweij PE, Zhang J, Debets AJ, Meis JF, van de Veerdonk FL, Schoustra SE, et al. In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect Dis. 2016;16(11):e251–e60. doi:10.1016/S1473-3099(16)30138-4.PubMedCrossRef

49.

Enserink M. Infectious diseases. Farm fungicides linked to resistance in a human pathogen. Science. 2009;326(5957):1173. doi:10.1126/science.326.5957.1173.PubMedCrossRef

50.

Fuhren J, Voskuil WS, Boel CH, Haas PJ, Hagen F, Meis JF, et al. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients. J Antimicrob Chemother. 2015;70(10):2894–8. doi:10.1093/jac/dkv177.PubMedCrossRef

51.

van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis. 2011;17(10):1846–54. doi:10.3201/eid1710.110226.PubMedPubMedCentralCrossRef

52.

Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Bruggemann RJ, Chowdhary A, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015;21–22:30–40. doi:10.1016/j.drup.2015.08.001.PubMedCrossRef

53.

Lionakis MS, Netea MG. Candida and host determinants of susceptibility to invasive candidiasis. PLoS Pathog. 2013;9(1):e1003079. doi:10.1371/journal.ppat.1003079.PubMedPubMedCentralCrossRef

54.

Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veerdonk FL. Immune defence against Candida fungal infections. Nat Rev Immunol. 2015;15(10):630–42. doi:10.1038/nri3897.PubMedCrossRef

55.

Drummond RA, Collar AL, Swamydas M, Rodriguez CA, Lim JK, Mendez LM, et al. CARD9-dependent neutrophil recruitment protects against fungal invasion of the central nervous system. PLoS Pathog. 2015;11(12):e1005293. doi:10.1371/journal.ppat.1005293.PubMedPubMedCentralCrossRef

56.

Drewniak A, Gazendam RP, Tool AT, van Houdt M, Jansen MH, van Hamme JL, et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood. 2013;121(13):2385–92. doi:10.1182/blood-2012-08-450551.PubMedCrossRef

57.

Lanternier F, Mahdaviani SA, Barbati E, Chaussade H, Koumar Y, Levy R, et al. Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. J Allergy Clin Immunol. 2015;135(6):1558–1568 e2. doi:10.1016/j.jaci.2014.12.1930.PubMedPubMedCentralCrossRef

58.

Rautemaa R, Richardson M, Pfaller M, Koukila-Kahkola P, Perheentupa J, Saxen H. Decreased susceptibility of Candida Albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J Antimicrob Chemother. 2007;60(4):889–92. doi:10.1093/jac/dkm299.PubMedCrossRef

59.

Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359(9312):1135–44. doi:10.1016/S0140-6736(02)08162-X.PubMedCrossRef

60.

Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41–4. doi:10.1111/j.1348-0421.2008.00083.x.PubMedCrossRef

61.

Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the first seven reported cases of candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. MMWR Morb Mortal Wkly Rep. 2016;65(44):1234–7. doi:10.15585/mmwr.mm6544e1.PubMedCrossRef

62.

Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, et al. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Inf Secur. 2016;73(4):369–74. doi:10.1016/j.jinf.2016.07.008.

63.

Emara M, Ahmad S, Khan Z, Joseph L, Al-Obaid I, Purohit P, et al. Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis. 2015;21(6):1091–2. doi:10.3201/eid2106.150270.PubMedPubMedCentralCrossRef

64.

Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134–40. doi:10.1093/cid/ciw691.PubMedCrossRef

65.

Patel RV, Shaeer KM, Patel P, Garmaza A, Wiangkham K, Franks RB, et al. EPA-registered repellents for mosquitoes transmitting emerging viral disease. Pharmacotherapy. 2016;36(12):1272–80. doi:10.1002/phar.1854.PubMedCrossRef

66.

Sambri V, Capobianchi M, Charrel R, Fyodorova M, Gaibani P, Gould E, et al. West Nile virus in Europe: emergence, epidemiology, diagnosis, treatment, and prevention. Clin Microbiol Infect. 2013;19(8):699–704. doi:10.1111/1469-0691.12211.PubMedCrossRef

67.

Montgomery RR, Murray KO. Risk factors for West Nile virus infection and disease in populations and individuals. Expert Rev Anti-Infect Ther. 2015;13(3):317–25. doi:10.1586/14787210.2015.1007043.PubMedPubMedCentralCrossRef

68.

Qian F, Goel G, Meng H, Wang X, You F, Devine L, et al. Systems immunology reveals markers of susceptibility to West Nile virus infection. Clin Vaccine Immunol. 2015;22(1):6–16. doi:10.1128/CVI.00508-14.PubMedCrossRef

69.

McBath A, Stafford R, Antony SJ. Idiopathic CD4 lymphopenia associated with neuroinvasive West Nile disease: case report and review of the literature. J Infect Public Health. 2014;7(2):170–3. doi:10.1016/j.jiph.2013.09.003.PubMedCrossRef

70.

Alonto AM, Aronoff DM, Malani PN. West Nile virus meningitis in patient with common variable immunodeficiency. Emerg Infect Dis. 2003;9(10):1353–4. doi:10.3201/eid0910.030195.PubMedPubMedCentralCrossRef

71.

Morjaria S, Arguello E, Taur Y, Sepkowitz K, Hatzoglou V, Nemade A, et al. West Nile Virus central nervous system infection in patients treated with rituximab: implications for diagnosis and prognosis, with a review of literature. Open Forum Infect Dis. 2015;2(4):ofv136. doi:10.1093/ofid/ofv136.PubMedPubMedCentralCrossRef

72.

Furuya-Kanamori L, Liang S, Milinovich G, Soares Magalhaes RJ, Clements AC, Hu W, et al. Co-distribution and co-infection of chikungunya and dengue viruses. BMC Infect Dis. 2016;16:84. doi:10.1186/s12879-016-1417-2.PubMedPubMedCentralCrossRef

73.

Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11(3):480–96.PubMedPubMedCentral

74.

Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21(st) century. Trop Med Health. 2011;39(4 Suppl):3–11. doi:10.2149/tmh.2011-S05.PubMedPubMedCentralCrossRef

75.

Maia SH, Brasil IR, Esmeraldo Rde M, Ponte CN, Costa RC, Lira RA. Severe dengue in the early postoperative period after kidney transplantation: two case reports from Hospital Geral de Fortaleza. Rev Soc Bras Med Trop. 2015;48(6):783–5. doi:10.1590/0037-8682-0205-2015.PubMedCrossRef

76.

Tan FL, Loh DL, Prabhakaran K, Tambyah PA, Yap HK. Dengue haemorrhagic fever after living donor renal transplantation. Nephrol Dial Transplant. 2005;20(2):447–8. doi:10.1093/ndt/gfh601.PubMedCrossRef

77.

Garcia JH, Rocha TD, Viana CF, Goncalves BP, Girao ES, Vasconcelos JB, et al. Dengue shock syndrome in a liver transplant recipient. Transplantation. 2006;82(6):850–1. doi:10.1097/01.tp.0000235151.60237.fe.PubMedCrossRef

78.

Nasim A, Anis S, Baqi S, Akhtar SF, Baig-Ansari N. Clinical presentation and outcome of dengue viral infection in live-related renal transplant recipients in Karachi. Pakistan Transpl Infect Dis. 2013;15(5):516–25. doi:10.1111/tid.12114.PubMed

79.

Dengue vaccine: WHO position paper - July 2016. Wkly Epidemiol Rec. 2016;91(30):349–64.

80.

Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44(6):850–6. doi:10.1086/511869.PubMedCrossRef

81.

Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE, et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11(5):e1001638. doi:10.1371/journal.pmed.1001638.PubMedPubMedCentralCrossRef

82.

Lazear HM, Diamond MS. Zika virus: new clinical syndromes and its emergence in the western hemisphere. J Virol. 2016;90(10):4864–75. doi:10.1128/JVI.00252-16.PubMedPubMedCentralCrossRef

83.

Lanteri MC, Kleinman SH, Glynn SA, Musso D, Keith Hoots W, Custer BS, et al. Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications. Transfusion (Paris). 2016;56(7):1907–14. doi:10.1111/trf.13677.CrossRef

84.

Musso D, Roche C, Nhan TX, Robin E, Teissier A, Cao-Lormeau VM. Detection of Zika virus in saliva. J Clin Virol. 2015;68:53–5. doi:10.1016/j.jcv.2015.04.021.PubMedCrossRef

85.

Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. Emerg Infect Dis. 2015;21(2):359–61. doi:10.3201/eid2102.141363.PubMedPubMedCentralCrossRef

86.

Swaminathan S, Schlaberg R, Lewis J, Hanson KE, Couturier MR. Fatal Zika virus infection with secondary nonsexual transmission. N Engl J Med. 2016;375(19):1907–9. doi:10.1056/NEJMc1610613.PubMedPubMedCentralCrossRef

87.

Oliveira DB, Almeida FJ, Durigon EL, Mendes EA, Braconi CT, Marchetti I, et al. Prolonged shedding of Zika virus associated with congenital infection. N Engl J Med. 2016;375(12):1202–4. doi:10.1056/NEJMc1607583.PubMedCrossRef

88.

Sampathkumar P, Sanchez JL. Zika virus in the Americas: a review for clinicians. Mayo Clin Proc. 2016;91(4):514–21. doi:10.1016/j.mayocp.2016.02.017.PubMedCrossRef

89.

Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951–8. doi:10.1056/NEJMoa1600651.PubMedCrossRef

90.

Deller JJ Jr, Russell PK. Chikungunya disease. Am J Trop Med Hyg. 1968;17(1):107–11.PubMedCrossRef

91.

Halstead SB, Udomsakdi S, Singharaj P, Nisalak A. Dengue chikungunya virus infection in man in Thailand, 1962-1964. 3. Clinical, epidemiologic, and virologic observations on disease in non-indigenous white persons. Am J Trop Med Hyg. 1969;18(6):984–96.PubMedCrossRef

92.

Inamadar AC, Palit A, Sampagavi VV, Raghunath S, Deshmukh NS. Cutaneous manifestations of chikungunya fever: observations made during a recent outbreak in south India. Int J Dermatol. 2008;47(2):154–9. doi:10.1111/j.1365-4632.2008.03478.x.PubMedCrossRef

93.

Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis. 2008;47(4):469–75. doi:10.1086/590003.PubMedCrossRef

94.

Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis. 2009;49(6):942–8. doi:10.1086/605496.PubMedCrossRef

95.

Kee AC, Yang S, Tambyah P. Atypical chikungunya virus infections in immunocompromised patients. Emerg Infect Dis. 2010;16(6):1038–40. doi:10.3201/eid1606.091115.PubMedPubMedCentralCrossRef

96.

Kositpantawong N, Charoenmak B, Siripaitoon P, Silpapojakul K. Clinical presentations and interactions of the chikungunya viral infection in HIV patients during the chikungunya epidemic in southern Thailand. Open Forum Infect Dis. 2014;1(supp 1):S462–S3.CrossRef

97.

Filbin MR, Mylonakis EE, Callegari L, Legome E. Babesiosis. J Emerg Med. 2001;20(1):21–4.PubMedCrossRef

98.

Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008;46(3):370–6. doi:10.1086/525852.PubMedCrossRef

99.

Froberg MK, Dannen D, Bakken JS. Babesiosis and HIV. Lancet. 2004;363(9410):704. doi:10.1016/S0140-6736(04)15645-6.PubMedCrossRef

100.

Rosner F, Zarrabi MH, Benach JL, Habicht GS. Babesiosis in splenectomized adults. Review of 22 reported cases. Am J Med. 1984;76(4):696–701.PubMedCrossRef

101.

Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, et al. The limits and intensity of plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med. 2008;5(2):e38. doi:10.1371/journal.pmed.0050038.PubMedPubMedCentralCrossRef

102.

ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg. 2004;71(2 Suppl):41–54.PubMed

103.

Chandramohan D, Greenwood BM. Is there an interaction between human immunodeficiency virus and Plasmodium falciparum? Int J Epidemiol. 1998;27(2):296–301.PubMedCrossRef

104.

Chotivanich K, Udomsangpetch R, McGready R, Proux S, Newton P, Pukrittayakamee S, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis. 2002;185(10):1538–41. doi:10.1086/340213.PubMedCrossRef

105.

Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg. 1991;45(3):297–308.PubMedCrossRef

106.

Mourao LC, Morais CG, Bueno LL, Jimenez MC, Soares IS, Fontes CJ, et al. Naturally acquired antibodies to Plasmodium vivax blood-stage vaccine candidates (PvMSP-1₁₉ and PvMSP-3α_359−798) and their relationship with hematological features in malaria patients from the Brazilian Amazon. Microbes Infect. 2012;14(9):730–9. doi:10.1016/j.micinf.2012.02.011.PubMedCrossRef

107.

Engwerda CR, Kaye PM. Organ-specific immune responses associated with infectious disease. Immunol Today. 2000;21(2):73–8.PubMedCrossRef

108.

Gardener PJ. Taxonomy of the genus Leishmania: a review of nomenclature and classification. Trop Dis Bull. 1977;74(12):1069–88.PubMed

109.

Banuls AL, Hide M, Prugnolle F. Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol. 2007;64:1–109. doi:10.1016/S0065-308X(06)64001-3.PubMedCrossRef

110.

Bashaye S, Nombela N, Argaw D, Mulugeta A, Herrero M, Nieto J, et al. Risk factors for visceral leishmaniasis in a new epidemic site in Amhara region. Ethiopia Am J Trop Med Hyg. 2009;81(1):34–9.PubMed

111.

Wolday D, Berhe N, Akuffo H, Desjeux P, Britton S. Emerging Leishmania/HIV co-infection in Africa. Med Microbiol Immunol. 2001;190(1–2):65–7.PubMedCrossRef

112.

Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–359, table of contents. doi:10.1128/CMR.00061-07.PubMedPubMedCentralCrossRef

113.

Jarvis JN, Lockwood DN. Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis. 2013;26(1):1–9. doi:10.1097/QCO.0b013e32835c2198.PubMedCrossRef

114.

de Silva AA, Pacheco e Silva Filho A, Sesso Rde C, Esmeraldo Rde M, de Oliveira CM, Fernandes PF, et al. Epidemiologic, clinical, diagnostic and therapeutic aspects of visceral leishmaniasis in renal transplant recipients: experience from thirty cases. BMC Infect Dis. 2015;15:96. doi:10.1186/s12879-015-0852-9.PubMedPubMedCentralCrossRef

115.

Descoteaux A, Turco SJ. The lipophosphoglycan of Leishmania and macrophage protein kinase C. Parasitol Today. 1993;9(12):468–71.PubMedCrossRef

116.

Jayakumar A, Donovan MJ, Tripathi V, Ramalho-Ortigao M, McDowell MA. Leishmania major infection activates NF-kappaB and interferon regulatory factors 1 and 8 in human dendritic cells. Infect Immun. 2008;76(5):2138–48. doi:10.1128/IAI.01252-07.PubMedPubMedCentralCrossRef

117.

Jayakumar A, Widenmaier R, Ma X, McDowell MA. Transcriptional inhibition of interleukin-12 promoter activity in Leishmania spp.-infected macrophages. J Parasitol. 2008;94(1):84–93. doi:10.1645/GE-1153.1.PubMedPubMedCentralCrossRef

118.

Sanal O, Turkkani G, Gumruk F, Yel L, Secmeer G, Tezcan I, et al. A case of interleukin-12 receptor beta-1 deficiency with recurrent leishmaniasis. Pediatr Infect Dis J. 2007;26(4):366–8. doi:10.1097/01.inf.0000258696.64507.0f.PubMedCrossRef

119.

Asensi V, Tricas L, Meana A, Roos D, Carton JA, Maradona JA, et al. Visceral leishmaniasis and other severe infections in an adult patient with p47-phox-deficient chronic granulomatous disease. Infection. 2000;28(3):171–4.PubMedCrossRef

120.

Bode SF, Ammann S, Al-Herz W, Bataneant M, Dvorak CC, Gehring S, et al. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica. 2015;100(7):978–88. doi:10.3324/haematol.2014.121608.PubMedPubMedCentralCrossRef

121.

Walker DH. Rickettsiae and rickettsial infections: the current state of knowledge. Clin Infect Dis. 2007;45(Suppl 1):S39–44. doi:10.1086/518145.PubMedCrossRef

122.

Jensenius M, Fournier PE, Raoult D. Rickettsioses and the international traveler. Clin Infect Dis. 2004;39(10):1493–9. doi:10.1086/425365.PubMedCrossRef

123.

Jensenius M, Fournier PE, Raoult D. Tick-borne rickettsioses in international travellers. Int J Infect Dis. 2004;8(3):139–46. doi:10.1016/j.ijid.2003.06.004.PubMedCrossRef

124.

Jensenius M, Parola P, Raoult D. Threats to international travellers posed by tick-borne diseases. Travel Med Infect Dis. 2006;4(1):4–13. doi:10.1016/j.tmaid.2004.11.003.PubMedCrossRef

125.

Walker DH, Fishbein DB. Epidemiology of rickettsial diseases. Eur J Epidemiol. 1991;7(3):237–45.PubMedCrossRef

126.

Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, Kernif T, et al. Update on tick-borne rickettsioses around the world: a geographic approach. Clin Microbiol Rev. 2013;26(4):657–702. doi:10.1128/CMR.00032-13.PubMedPubMedCentralCrossRef

127.

Oteo JA, Portillo A. Tick-borne rickettsioses in Europe. Ticks Tick Borne Dis. 2012;3(5–6):271–8. doi:10.1016/j.ttbdis.2012.10.035.PubMedCrossRef

128.

Lindgren E, Gustafson R. Tick-borne encephalitis in Sweden and climate change. Lancet. 2001;358(9275):16–8. doi:10.1016/S0140-6736(00)05250-8.PubMedCrossRef

129.

Paddock CD, Childs JE. Ehrlichia chaffeensis: a prototypical emerging pathogen. Clin Microbiol Rev. 2003;16(1):37–64.PubMedPubMedCentralCrossRef

130.

Drexler NA, Dahlgren FS, Heitman KN, Massung RF, Paddock CD, Behravesh CB. National Surveillance of spotted fever group rickettsioses in the United States, 2008-2012. Am J Trop Med Hyg. 2016;94(1):26–34. doi:10.4269/ajtmh.15-0472.PubMedPubMedCentralCrossRef

131.

Esbenshade A, Esbenshade J, Domm J, Williams J, Frangoul H. Severe ehrlichia infection in pediatric oncology and stem cell transplant patients. Pediatr Blood Cancer. 2010;54(5):776–8. doi:10.1002/pbc.22392.PubMed

132.

Paddock CD, Folk SM, Shore GM, Machado LJ, Huycke MM, Slater LN, et al. Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virus. Clin Infect Dis. 2001;33(9):1586–94. doi:10.1086/323981.PubMedCrossRef

133.

Chapman AS, Bakken JS, Folk SM, Paddock CD, Bloch KC, Krusell A, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis—United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep. 2006;55(RR-4):1–27.

134.

Cascio A, Colomba C, Antinori S, Paterson DL, Titone L. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial. Clin Infect Dis. 2002;34(2):154–8. doi:10.1086/338068.PubMedCrossRef

135.

Bakken JS, Dumler JS. Clinical diagnosis and treatment of human granulocytotropic anaplasmosis. Ann N Y Acad Sci. 2006;1078:236–47. doi:10.1196/annals.1374.042.PubMedCrossRef

136.

Ismail N, Bloch KC, McBride JW. Human ehrlichiosis and anaplasmosis. Clin Lab Med. 2010;30(1):261–92. doi:10.1016/j.cll.2009.10.004.PubMedPubMedCentralCrossRef

137.

Pesquera C, Portillo A, Palomar AM, Oteo JA. Investigation of tick-borne bacteria (Rickettsia spp., Anaplasma spp., Ehrlichia spp. and Borrelia spp.) in ticks collected from Andean tapirs, cattle and vegetation from a protected area in Ecuador. Parasit Vectors. 2015;8:46. doi:10.1186/s13071-015-0662-3.PubMedPubMedCentralCrossRef

138.

Dumler JS. The biological basis of severe outcomes in Anaplasma phagocytophilum infection. FEMS Immunol Med Microbiol. 2012;64(1):13–20. doi:10.1111/j.1574-695X.2011.00909.x.PubMedCrossRef

139.

Otrock ZK, Gonzalez MD, Eby CS. Ehrlichia-induced hemophagocytic lymphohistiocytosis: a case series and review of literature. Blood Cells Mol Dis. 2015;55(3):191–3. doi:10.1016/j.bcmd.2015.06.009.PubMedCrossRef

140.

Anderson A, Bijlmer H, Fournier PE, Graves S, Hartzell J, Kersh GJ, et al. Diagnosis and management of Q fever—United States, 2013: recommendations from CDC and the Q Fever Working Group. MMWR Recomm Rep. 2013;(62, RR-03):1–30.

141.

Hartzell JD, Gleeson T, Scoville S, Massung RF, Wortmann G, Martin GJ. Practice guidelines for the diagnosis and management of patients with Q fever by the Armed Forces Infectious Diseases Society. Mil Med. 2012;177(5):484–94.PubMedCrossRef

142.

Raoult D, Levy PY, Dupont HT, Chicheportiche C, Tamalet C, Gastaut JA, et al. Q fever and HIV infection. AIDS. 1993;7(1):81–6.PubMedCrossRef

143.

Belec L, Gresenguet G, Ekala MT, Jacob A, Vohito MD, Cotigny S, et al. Coxiella burnetii infection among subjects infected with HIV type 1 in the Central African Republic. Eur J Clin Microbiol Infect Dis. 1993;12(10):775–8.PubMedCrossRef

144.

Meis JF, Weemaes CR, Horrevorts AM, Aerdts SJ, Westenend PJ, Galama JM. Rapidly fatal Q-fever pneumonia in a patient with chronic granulomatous disease. Infection. 1992;20(5):287–9.PubMedCrossRef

145.

Paine A, Miya T, Webb BJ. Coxiella burnetii infection with severe hyperferritinemia in an asplenic patient. Open Forum Infect Dis. 2015;2(4):ofv125. doi:10.1093/ofid/ofv125.PubMedPubMedCentralCrossRef

146.

Ohl ME, Spach DH. Bartonella quintana and urban trench fever. Clin Infect Dis. 2000;31(1):131–5. doi:10.1086/313890.PubMedCrossRef

147.

Breitschwerdt EB, Maggi RG, Nicholson WL, Cherry NA, Woods CW. Bartonella sp. bacteremia in patients with neurological and neurocognitive dysfunction. J Clin Microbiol. 2008;46(9):2856–61. doi:10.1128/JCM.00832-08.PubMedPubMedCentralCrossRef

148.

Maguina C, Gotuzzo E. Bartonellosis. New and old. Infect Dis Clin N Am. 2000;14(1):1–22. vii CrossRef

149.

Maguina C, Garcia PJ, Gotuzzo E, Cordero L, Spach DH. Bartonellosis (Carrion's disease) in the modern era. Clin Infect Dis. 2001;33(6):772–9. doi:10.1086/322614.PubMedCrossRef

150.

Mosepele M, Mazo D, Cohn J. Bartonella infection in immunocompromised hosts: Immunology of vascular infection and vasoproliferation. Clin Dev Immunol. 2012;2012:612809. doi:10.1155/2012/612809.PubMedCrossRef

151.

Koehler JE, Sanchez MA, Tye S, Garrido-Rowland CS, Chen FM, Maurer T, et al. Prevalence of Bartonella infection among human immunodeficiency virus-infected patients with fever. Clin Infect Dis. 2003;37(4):559–66. doi:10.1086/375586.PubMedCrossRef

152.

Rostad CA, McElroy AK, Hilinski JA, Thompson MP, Drew CP, Denison AM, et al. Bartonella henselae-mediated disease in solid organ transplant recipients: two pediatric cases and a literature review. Transpl Infect Dis. 2012;14(5):E71–81. doi:10.1111/j.1399-3062.2012.00774.x.PubMedCrossRef

153.

Psarros G, Riddell J, Gandhi T, Kauffman CA, Cinti SK. Bartonella henselae infections in solid organ transplant recipients: report of 5 cases and review of the literature. Medicine (Baltimore). 2012;91(2):111–21. doi:10.1097/MD.0b013e31824dc07a.CrossRef

154.

Moulin C, Kanitakis J, Ranchin B, Chauvet C, Gillet Y, Morelon E, et al. Cutaneous bacillary angiomatosis in renal transplant recipients: report of three new cases and literature review. Transpl Infect Dis. 2012;14(4):403–9. doi:10.1111/j.1399-3062.2011.00713.x.PubMedCrossRef

155.

Holmes NE, Opat S, Kelman A, Korman TM. Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia. J Med Microbiol. 2011;60(Pt 1):142–6. doi:10.1099/jmm.0.015867-0.PubMedCrossRef

156.

Koehler JE, Sanchez MA, Garrido CS, Whitfeld MJ, Chen FM, Berger TG, et al. Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med. 1997;337(26):1876–83. doi:10.1056/NEJM199712253372603.PubMedCrossRef

157.

Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 2003;82(6):373–84. doi:10.1097/01.md.0000100046.06009.b0.CrossRef

158.

Liston TE, Koehler JE. Granulomatous hepatitis and necrotizing splenitis due to Bartonella henselae in a patient with cancer: case report and review of hepatosplenic manifestations of bartonella infection. Clin Infect Dis. 1996;22(6):951–7.PubMedCrossRef

159.

VanderHeyden TR, Yong SL, Breitschwerdt EB, Maggi RG, Mihalik AR, Parada JP, et al. Granulomatous hepatitis due to Bartonella henselae infection in an immunocompetent patient. BMC Infect Dis. 2012;12:17. doi:10.1186/1471-2334-12-17.PubMedPubMedCentralCrossRef

160.

Bonatti H, Mendez J, Guerrero I, Krishna M, Ananda-Michel J, Yao J, et al. Disseminated Bartonella infection following liver transplantation. Transpl Int. 2006;19(8):683–7. doi:10.1111/j.1432-2277.2006.00336.x.PubMedCrossRef

161.

Goldenberger D, Claas GJ, Bloch-Infanger C, Breidthardt T, Suter B, Martinez M, et al. Louse-borne relapsing fever (Borrelia recurrentis) in an Eritrean refugee arriving in Switzerland, August 2015. Euro Surveill. 2015;20(32):2–5.PubMedCrossRef

162.

Ciervo A, Mancini F, di Bernardo F, Giammanco A, Vitale G, Dones P, et al. Louseborne relapsing fever in young migrants, Sicily, Italy, July-September 2015. Emerg Infect Dis. 2016;22(1):152–3. doi:10.3201/eid2201.151580.PubMedPubMedCentralCrossRef

163.

Dworkin MS, Schwan TG, Anderson DE Jr, Borchardt SM. Tick-borne relapsing fever. Infect Dis Clin N Am. 2008;22(3):449–468, viii. doi:10.1016/j.idc.2008.03.006.CrossRef

164.

Hovius JW, de Wever B, Sohne M, Brouwer MC, Coumou J, Wagemakers A, et al. A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet. 2013;382(9892):658. doi:10.1016/S0140-6736(13)61644-X.PubMedPubMedCentralCrossRef

165.

Gugliotta JL, Goethert HK, Berardi VP, Telford SR III. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med. 2013;368(3):240–5. doi:10.1056/NEJMoa1209039.PubMedPubMedCentralCrossRef

166.

Steere AC. Lyme disease. N Engl J Med. 1989;321(9):586–96. doi:10.1056/NEJM198908313210906.PubMedCrossRef

167.

Krause PJ, McKay K, Thompson CA, Sikand VK, Lentz R, Lepore T, et al. Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis. 2002;34(9):1184–91. doi:10.1086/339813.PubMedCrossRef

168.

Horowitz HW, Aguero-Rosenfeld ME, Holmgren D, McKenna D, Schwartz I, Cox ME, et al. Lyme disease and human granulocytic anaplasmosis coinfection: Impact of case definition on coinfection rates and illness severity. Clin Infect Dis. 2013;56(1):93–9. doi:10.1093/cid/cis852.PubMedCrossRef

169.

Li X, McHugh GA, Damle N, Sikand VK, Glickstein L, Steere AC. Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or lyme arthritis. Arthritis Rheum. 2011;63(8):2238–47. doi:10.1002/art.30384.PubMedPubMedCentralCrossRef

170.

Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089–134. doi:10.1086/508667.PubMedCrossRef

171.

Damle AS, Gaikwad AA, Patwardhan NS, Duthade MM, Sheikh NS, Deshmukh DG. Outbreak of human buffalopox infection. J Glob Infect Dis. 2011;3(2):187–8. doi:10.4103/0974-777X.81698.PubMedPubMedCentralCrossRef

172.

Riyesh T, Karuppusamy S, Bera BC, Barua S, Virmani N, Yadav S, et al. Laboratory-acquired buffalopox virus infection. India Emerg Infect Dis. 2014;20(2):324–6. doi:10.3201/eid2002.130358.PubMedCrossRef

173.

Kilic SS, Puel A, Casanova JL. Orf infection in a patient with Stat1 gain-of-function. J Clin Immunol. 2015;35(1):80–3. doi:10.1007/s10875-014-0111-7.PubMedCrossRef

174.

Geerinck K, Lukito G, Snoeck R, De Vos R, De Clercq E, Vanrenterghem Y, et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol. 2001;64(4):543–9.PubMedCrossRef

175.

Liu J, Tian W, Wang F, Teng W, Zhang Y, Tong C, et al. Maternal onset de novo SH2D1A mutation and lymphocytic choriomeningitis virus infection in a patient with Xlinked lymphoproliferative disease type 1: a case report. Mol Med Rep. 2015;11(5):3291–4. doi:10.3892/mmr.2015.3173.PubMedPubMedCentral

176.

Maranan MC, Schiff D, Johnson DC, Abrahams C, Wylam M, Gerber SI. Pneumonic tularemia in a patient with chronic granulomatous disease. Clin Infect Dis. 1997;25(3):630–3.PubMedCrossRef

177.

Lam SK, Chua KB. Nipah virus encephalitis outbreak in Malaysia. Clin Infect Dis. 2002;34(Suppl 2):S48–51. doi:10.1086/338818.PubMedCrossRef

178.

Hsu VP, Hossain MJ, Parashar UD, Ali MM, Ksiazek TG, Kuzmin I, et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis. 2004;10(12):2082–7. doi:10.3201/eid1012.040701.PubMedPubMedCentralCrossRef

179.

de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–34. doi:10.1038/nrmicro.2016.81.PubMedCrossRef

180.

Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. doi:10.1016/j.tim.2016.03.003.PubMedCrossRef

181.

Wong G, Liu W, Liu Y, Zhou B, Bi Y, Gao GF. MERS, SARS, and Ebola: the role of super-spreaders in infectious disease. Cell Host Microbe. 2015;18(4):398–401. doi:10.1016/j.chom.2015.09.013.PubMedCrossRef

182.

Cho SY, Kang JM, Ha YE, Park GE, Lee JY, Ko JH, et al. MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study. Lancet. 2016;388(10048):994–1001. doi:10.1016/S0140-6736(16)30623-7.PubMedCrossRef

183.

Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–47. doi:10.1038/nrd.2015.37.PubMedCrossRef

184.

Ip WK, Chan KH, Law HK, Tso GH, Kong EK, Wong WH, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis. 2005;191(10):1697–704. doi:10.1086/429631.PubMedCrossRef

185.

Tu X, Chong WP, Zhai Y, Zhang H, Zhang F, Wang S, et al. Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect. 2015;71(1):101–9. doi:10.1016/j.jinf.2015.03.006.PubMedCrossRef

186.

Zhang H, Zhou G, Zhi L, Yang H, Zhai Y, Dong X, et al. Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect Dis. 2005;192(8):1355–61. doi:10.1086/491479.PubMedCrossRef

187.

Duncan CJ, Mohamad SM, Young DF, Skelton AJ, Leahy TR, Munday DC, et al. Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci Transl Med. 2015;7(307):307ra154. doi:10.1126/scitranslmed.aac4227.PubMedPubMedCentralCrossRef

188.

Hambleton S, Goodbourn S, Young DF, Dickinson P, Mohamad SM, Valappil M, et al. STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci U S A. 2013;110(8):3053–8. doi:10.1073/pnas.1220098110.PubMedPubMedCentralCrossRef

189.

Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554–61. doi:10.3201/eid2209.151164.PubMedPubMedCentralCrossRef

190.

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi:10.1093/infdis/jiu396.PubMedCrossRef

191.

Hartman AL, Towner JS, Nichol ST. Ebola and marburg hemorrhagic fever. Clin Lab Med. 2010;30(1):161–77. doi:10.1016/j.cll.2009.12.001.PubMedCrossRef

192.

Leendertz SA, Gogarten JF, Dux A, Calvignac-Spencer S, Leendertz FH. Assessing the evidence supporting fruit bats as the primary reservoirs for Ebola viruses. EcoHealth. 2016;13(1):18–25. doi:10.1007/s10393-015-1053-0.PubMedCrossRef

193.

Mari Saez A, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Dux A, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med. 2014;7(1):17–23. doi:10.15252/emmm.201404792.PubMedCentralCrossRef

194.

Gupta M, Spiropoulou C, Rollin PE. Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology. 2007;364(1):45–54. doi:10.1016/j.virol.2007.02.017.PubMedCrossRef

195.

Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010;4(10). doi:10.1371/journal.pntd.0000837.

196.

van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42. doi:10.1056/NEJMoa1511812.PubMedCrossRef

197.

Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2016; doi:10.1016/S0140-6736(16)32621-6.

198.

Merler S, Ajelli M, Fumanelli L, Parlamento S, Pastore YPA, Dean NE, et al. Containing Ebola at the source with ring vaccination. PLoS Negl Trop Dis. 2016;10(11):e0005093. doi:10.1371/journal.pntd.0005093.PubMedPubMedCentralCrossRef

199.

Pavio N, Meng XJ, Renou C. Zoonotic hepatitis E: animal reservoirs and emerging risks. Vet Res. 2010;41(6):46. doi:10.1051/vetres/2010018.PubMedPubMedCentralCrossRef

200.

Yazaki Y, Mizuo H, Takahashi M, Nishizawa T, Sasaki N, Gotanda Y, et al. Sporadic acute or fulminant hepatitis E in Hokkaido, Japan, may be food-borne, as suggested by the presence of hepatitis E virus in pig liver as food. J Gen Virol. 2003;84(Pt 9):2351–7. doi:10.1099/vir.0.19242-0.PubMedCrossRef

201.

Feagins AR, Opriessnig T, Guenette DK, Halbur PG, Meng XJ. Inactivation of infectious hepatitis E virus present in commercial pig livers sold in local grocery stores in the United States. Int J Food Microbiol. 2008;123(1–2):32–7. doi:10.1016/j.ijfoodmicro.2007.11.068.PubMedCrossRef

202.

Peron JM, Bureau C, Poirson H, Mansuy JM, Alric L, Selves J, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat. 2007;14(5):298–303. doi:10.1111/j.1365-2893.2007.00858.x.PubMedCrossRef

203.

Versluis J, Pas SD, Agteresch HJ, de Man RA, Maaskant J, Schipper ME, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(6):1079–86. doi:10.1182/blood-2013-03-492363.PubMedCrossRef

204.

Kamar N, Mansuy JM, Cointault O, Selves J, Abravanel F, Danjoux M, et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant. 2008;8(8):1744–8. doi:10.1111/j.1600-6143.2008.02286.x.PubMedCrossRef

205.

Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811–7. doi:10.1056/NEJMoa0706992.PubMedCrossRef

206.

le Coutre P, Meisel H, Hofmann J, Rocken C, Vuong GL, Neuburger S, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut. 2009;58(5):699–702. doi:10.1136/gut.2008.165571.PubMedCrossRef

207.

Severe morbidity and mortality associated with influenza in children and young adults--Michigan, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(35):837–40.

208.

Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis. 2006;43(5):564–8. doi:10.1086/506352.PubMedCrossRef

209.

Abrahams A, Hallows N, French H. A further investigation into influenza pneumococcal and influenzal-streptococcal septicaemia: epidemic influenzal pneumonia of highly fatal types and it relation to purulent bronchitis. Lancet. 1919;1919:1–11.CrossRef

210.

Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6(5):303–12. doi:10.1016/S1473-3099(06)70466-2.PubMedCrossRef

211.

Stohr K. Influenza—WHO cares. Lancet Infect Dis. 2002;2(9):517.PubMedCrossRef

212.

Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, et al. The global circulation of seasonal influenza A (H3N2) viruses. Science. 2008;320(5874):340–6. doi:10.1126/science.1154137.PubMedCrossRef

213.

Ciancanelli MJ, Huang SX, Luthra P, Garner H, Itan Y, Volpi S, et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science. 2015;348(6233):448–53. doi:10.1126/science.aaa1578.PubMedPubMedCentralCrossRef

214.

Mak CM, Lam CW, Fong NC, Siu WK, Lee HC, Siu TS, et al. Fatal viral infection-associated encephalopathy in two Chinese boys: a genetically determined risk factor of thermolabile carnitine palmitoyltransferase II variants. J Hum Genet. 2011;56(8):617–21. doi:10.1038/jhg.2011.63.PubMedCrossRef

215.

Rajao DS, Loving CL, Waide EH, Gauger PC, Dekkers JC, Tuggle CK, et al. Pigs with severe combined immunodeficiency are impaired in controlling influenza a virus infection. J Innate Immun. 2016; doi:10.1159/000451007.

216.

Gordon CL, Johnson PD, Permezel M, Holmes NE, Gutteridge G, McDonald CF, et al. Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin Infect Dis. 2010;50(5):672–8. doi:10.1086/650462.PubMed

217.

Sakai E, Yamamoto T, Yamamoto K, Mizoguchi Y, Kaneno H, Ihashi M, et al. IgG3 deficiency and severity of 2009 pandemic H1N1 influenza. Pediatr Int. 2012;54(6):758–61. doi:10.1111/j.1442-200X.2012.03691.x.PubMedCrossRef

218.

Hanitsch LG, Lobel M, Mieves JF, Bauer S, Babel N, Schweiger B, et al. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency. Vaccine. 2016;34(21):2417–23. doi:10.1016/j.vaccine.2016.03.091.PubMedCrossRef

219.

Liu Y, Wu Y, Lam KT, Lee PP, Tu W, Lau YL. Dendritic and T cell response to influenza is normal in the patients with X-linked agammaglobulinemia. J Clin Immunol. 2012;32(3):421–9. doi:10.1007/s10875-011-9639-y.PubMedPubMedCentralCrossRef

220.

Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004;189(Suppl 1):S4–16. doi:10.1086/377712.PubMedCrossRef

221.

Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 1992;267(9):1237–41.PubMedCrossRef

222.

Mustafa MM, Weitman SD, Winick NJ, Bellini WJ, Timmons CF, Siegel JD. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis. 1993;16(5):654–60.PubMedCrossRef

223.

Cotugno N, Finocchi A, Cagigi A, Di Matteo G, Chiriaco M, Di Cesare S, et al. Defective B-cell proliferation and maintenance of long-term memory in patients with chronic granulomatous disease. J Allergy Clin Immunol. 2015;135(3):753–761 e2. doi:10.1016/j.jaci.2014.07.012.PubMedCrossRef

224.

Freeman AF, Jacobsohn DA, Shulman ST, Bellini WJ, Jaggi P, de Leon G, et al. A new complication of stem cell transplantation: measles inclusion body encephalitis. Pediatrics. 2004;114(5):e657–60. doi:10.1542/peds.2004-0949.PubMedCrossRef

225.

HQ ML, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease C, Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-04):1–34.

226.

Kadambari S, Bukasa A, Okike IO, Pebody R, Brown D, Gallimore C, et al. Enterovirus infections in England and Wales, 2000-2011: the impact of increased molecular diagnostics. Clin Microbiol Infect. 2014;20(12):1289–96. doi:10.1111/1469-0691.12753.PubMedCrossRef

227.

Berger JR, Chumley W, Pittman T, Given C, Nuovo G. Persistent Coxsackie B encephalitis: report of a case and review of the literature. J Neuro-Oncol. 2006;12(6):511–6. doi:10.1080/13550280601090546.

228.

Tebruegge M, Curtis N. Enterovirus infections in neonates. Semin Fetal Neonatal Med. 2009;14(4):222–7. doi:10.1016/j.siny.2009.02.002.PubMedCrossRef

229.

Lugo D, Krogstad P. Enteroviruses in the early 21st century: new manifestations and challenges. Curr Opin Pediatr. 2016;28(1):107–13. doi:10.1097/MOP.0000000000000303.PubMedPubMedCentralCrossRef

230.

Khetsuriani N, Lamonte A, Oberste MS, Pallansch M. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983-2003. Pediatr Infect Dis J. 2006;25(10):889–93. doi:10.1097/01.inf.0000237798.07462.32.PubMedCrossRef

231.

Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, et al. Clinical features of acute and fulminant myocarditis in children—2nd Nationwide Survey by Japanese Society of Pediatric Cardiology and Cardiac Surgery. Circ J. 2016;80(11):2362–8. doi:10.1253/circj.CJ-16-0234.PubMedCrossRef

232.

de Graaf H, Pelosi E, Cooper A, Pappachan J, Sykes K, MacIntosh I, et al. Severe enterovirus infections in hospitalized children in the south of England: clinical phenotypes and causative genotypes. Pediatr Infect Dis J. 2016;35(7):723–7. doi:10.1097/INF.0000000000001093.PubMedPubMedCentralCrossRef

233.

De Petris L, Gianviti A, Caione D, Innocenzi D, Edefonti A, Montini G, et al. Role of non-polio enterovirus infection in pediatric hemolytic uremic syndrome. Pediatr Nephrol. 2002;17(10):852–5. doi:10.1007/s00467-002-0966-3.PubMedCrossRef

234.

Sawyer MH. Enterovirus infections: diagnosis and treatment. Semin Pediatr Infect Dis. 2002;13(1):40–7.PubMedCrossRef

235.

Vuorinen T, Vainionpaa R, Hyypia T. Five years' experience of reverse-transcriptase polymerase chain reaction in daily diagnosis of enterovirus and rhinovirus infections. Clin Infect Dis. 2003;37(3):452–5. doi:10.1086/376635.PubMedCrossRef

236.

Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sanchez PJ, et al. A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis. J Pediatric Infect Dis Soc. 2016;5(1):53–62. doi:10.1093/jpids/piv015.PubMedCrossRef

237.

Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024–32. doi:10.1016/S0140-6736(13)61049-1.PubMedCrossRef

238.

Halliday E, Winkelstein J, Webster AD. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J Inf Secur. 2003;46(1):1–8.

239.

Driss N, Ben-Mustapha I, Mellouli F, Ben Yahia A, Touzi H, Bejaoui M, et al. High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies. Clin Vaccine Immunol. 2012;19(10):1684–9. doi:10.1128/CVI.00293-12.PubMedPubMedCentralCrossRef

240.

Driss N, Mellouli F, Ben Yahia A, Touzi H, Barbouche MR, Triki H, et al. Sequential asymptomatic enterovirus infections in a patient with major histocompatibility complex class II primary immunodeficiency. J Clin Microbiol. 2014;52(9):3486–9. doi:10.1128/JCM.01122-14.PubMedPubMedCentralCrossRef

241.

Gofshteyn J, Cardenas AM, Bearden D. Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked agammaglobulinemia. Pediatr Neurol. 2016;64:94–8. doi:10.1016/j.pediatrneurol.2016.06.014.PubMedCrossRef

242.

Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE. Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract. 2016;4(6):1059–65. doi:10.1016/j.jaip.2015.12.015.PubMedCrossRef

243.

NaserEddin A, Shamriz O, Keller B, Alzyoud RM, Unger S, Fisch P, et al. Enteroviral infection in a patient with BLNK adaptor protein deficiency. J Clin Immunol. 2015;35(4):356–60. doi:10.1007/s10875-015-0164-2.PubMedCrossRef

244.

Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P, et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis. 2003;36(3):e47–9. doi:10.1086/345746.PubMedCrossRef

245.

Palacios T, Bartelt L, Scheld W, Lopes MB, Kelting SM, Holland S, et al. Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy. Ann Allergy Asthma Immunol. 2015;115(2):148–50. doi:10.1016/j.anai.2015.05.007.PubMedPubMedCentralCrossRef

246.

Galama JM, Gielen M, Weemaes CM. Enterovirus antibody titers after IVIG replacement in agammaglobulinemic children. Clin Microbiol Infect. 2000;6(11):630–2.PubMedCrossRef

247.

Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296(5566):356–9. doi:10.1126/science.1068284.PubMedCrossRef

248.

Centers for Disease C, Prevention. Update on vaccine-derived polioviruses—worldwide, April 2011–June 2012. MMWR Morb Mortal Wkly Rep. 2012;61:741–6.

249.

Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol. 1998;36(10):2893–9.PubMedPubMedCentral

250.

McKinney RE Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis. 1987;9(2):334–56.PubMedCrossRef

251.

Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med. 1995;333(7):431–40. doi:10.1056/NEJM199508173330707.PubMedCrossRef

252.

Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch M, Kew O, et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis. 2003;188(12):1845–52. doi:10.1086/379791.PubMedCrossRef

253.

Shahmahmoodi S, Mamishi S, Aghamohammadi A, Aghazadeh N, Tabatabaie H, Gooya MM, et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995-2008. Emerg Infect Dis. 2010;16(7):1133–6. doi:10.3201/eid1607.091606.PubMedPubMedCentralCrossRef

254.

Hidalgo S, Garcia Erro M, Cisterna D, Freire MC. Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child. Pediatr Infect Dis J. 2003;22(6):570–2.PubMed

255.

von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis. 2002;2(12):744–50.CrossRef

256.

Vittucci AC, Spuri Vennarucci V, Grandin A, Russo C, Lancella L, Tozzi AE, et al. Pertussis in infants: an underestimated disease. BMC Infect Dis. 2016;16(1):414. doi:10.1186/s12879-016-1710-0.PubMedPubMedCentralCrossRef

257.

Orenstein WA. Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. Clin Infect Dis. 1999;28(Suppl 2):S147–50. doi:10.1086/515061.PubMedCrossRef

258.

Trainor EA, Nicholson TL, Merkel TJ. Bordetella pertussis transmission. Pathog Dis. 2015;73(8):ftv068. doi:10.1093/femspd/ftv068.PubMedPubMedCentralCrossRef

259.

Zlamy M. Rediscovering Pertussis. Front Pediatr. 2016;4:52. doi:10.3389/fped.2016.00052.PubMedPubMedCentralCrossRef

260.

Adam E, Church JA. Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy. J Clin Immunol. 2015;35(2):213–7. doi:10.1007/s10875-015-0131-y.PubMedCrossRef

261.

Yacoub A, Nanjappa S, Janz T, Greene JN. Infectious disease report: Bordetella pertussis infection in patients with cancer. Cancer Control. 2016;23(2):163–6.PubMedCrossRef

262.

Manchanda V, Gupta S, Bhalla P. Meningococcal disease: history, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention. Indian J Med Microbiol. 2006;24(1):7–19.PubMedCrossRef

263.

Tacon CL, Flower O. Diagnosis and management of bacterial meningitis in the paediatric population: a review. Emerg Med Int. 2012;2012:320309. doi:10.1155/2012/320309.PubMedPubMedCentralCrossRef

264.

Dupin N, Lecuyer H, Carlotti A, Poyart C, Coureuil M, Chanal J, et al. Chronic meningococcemia cutaneous lesions involve meningococcal perivascular invasion through the remodeling of endothelial barriers. Clin Infect Dis. 2012;54(8):1162–5. doi:10.1093/cid/cis120.PubMedCrossRef

265.

Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17. doi:10.1186/1478-7954-11-17.PubMedPubMedCentralCrossRef

266.

Achtman M. Epidemic spread and antigenic variability of Neisseria meningitidis. Trends Microbiol. 1995;3(5):186–92.PubMedCrossRef

267.

Zhu P, van der Ende A, Falush D, Brieske N, Morelli G, Linz B, et al. Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis. Proc Natl Acad Sci U S A. 2001;98(9):5234–9. doi:10.1073/pnas.061386098.PubMedPubMedCentralCrossRef

268.

Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, et al. The transmission of mycobacterium tuberculosis in high burden settings. Lancet Infect Dis. 2016;16(2):227–38. doi:10.1016/S1473-3099(15)00499-5.PubMedCrossRef

269.

Boisson-Dupuis S, Bustamante J, El-Baghdadi J, Camcioglu Y, Parvaneh N, El Azbaoui S, et al. Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. Immunol Rev. 2015;264(1):103–20. doi:10.1111/imr.12272.PubMedPubMedCentralCrossRef

270.

Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol. 2014;26(6):454–70. doi:10.1016/j.smim.2014.09.008.PubMedPubMedCentralCrossRef

271.

Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367(8):725–34. doi:10.1056/NEJMoa1111160.PubMedPubMedCentralCrossRef

272.

Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):e1–e33. doi:10.1093/cid/ciw694.PubMedCrossRef

273.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):853–67. doi:10.1093/cid/ciw566.PubMedCrossRef

274.

Rosenzweig SD, Holland SM. Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev. 2005;203:38–47. doi:10.1111/j.0105-2896.2005.00227.x.PubMedCrossRef

275.

Hsu AP, McReynolds LJ, Holland SM. GATA2 deficiency. Curr Opin Allergy Clin Immunol. 2015;15(1):104–9. doi:10.1097/ACI.0000000000000126.PubMedPubMedCentralCrossRef

276.

Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013;131(6):1624–34. doi:10.1016/j.jaci.2013.01.052.PubMedPubMedCentralCrossRef

277.

Lee PP, Lau YL. Endemic infections in Southeast Asia provide new insights to the phenotypic spectrum of primary immunodeficiency disorders. Asian Pac J Allergy Immunol. 2013;31(3):217–26.PubMed

278.

Odio CD, Milligan KL, McGowan K, Rudman Spergel AK, Bishop R, Boris L, et al. Endemic mycoses in patients with STAT3-mutated hyper-IgE (Job) syndrome. J Allergy Clin Immunol. 2015;136(5):1411–3 e1–2. doi:10.1016/j.jaci.2015.07.003.PubMedPubMedCentralCrossRef

279.

Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med. 2015;36(1):111–25. doi:10.1055/s-0034-1398389.PubMedCrossRef

280.

Limmathurotsakul D, Peacock SJ. Melioidosis: a clinical overview. Br Med Bull. 2011;99:125–39. doi:10.1093/bmb/ldr007.PubMedCrossRef

281.

Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18(2):383–416. doi:10.1128/CMR.18.2.383-416.2005.PubMedPubMedCentralCrossRef

282.

McLeod C, Morris PS, Bauert PA, Kilburn CJ, Ward LM, Baird RW, et al. Clinical presentation and medical management of melioidosis in children: a 24-year prospective study in the northern territory of Australia and review of the literature. Clin Infect Dis. 2015;60(1):21–6. doi:10.1093/cid/ciu733.PubMedCrossRef

283.

Benoit TJ, Blaney DD, Doker TJ, Gee JE, Elrod MG, Rolim DB, et al. A review of melioidosis cases in the Americas. Am J Trop Med Hyg. 2015;93(6):1134–9. doi:10.4269/ajtmh.15-0405.PubMedPubMedCentralCrossRef

284.

Dan M. Melioidosis in travelers: review of the literature. J Travel Med. 2015;22(6):410–4. doi:10.1111/jtm.12236.PubMedCrossRef

285.

Lau SK, Sridhar S, Ho CC, Chow WN, Lee KC, Lam CW, et al. Laboratory diagnosis of melioidosis: past, present and future. Exp Biol Med (Maywood). 2015;240(6):742–51. doi:10.1177/1535370215583801.CrossRef

286.

Sridhar S, Teng JL, Lau SK, Woo PC. Fatal bacteremic melioidosis in patients with prolonged neutropenia. Diagn Microbiol Infect Dis. 2016;84(3):258–60. doi:10.1016/j.diagmicrobio.2015.11.004.PubMedCrossRef

287.

Trabelsi H, Dendana F, Sellami A, Sellami H, Cheikhrouhou F, Neji S, et al. Pathogenic free-living amoebae: epidemiology and clinical review. Pathol Biol (Paris). 2012;60(6):399–405. doi:10.1016/j.patbio.2012.03.002.CrossRef

288.

Siddiqui R, Khan NA. Primary amoebic meningoencephalitis caused by Naegleria Fowleri: An old enemy presenting new challenges. PLoS Negl Trop Dis. 2014;8(8):e3017. doi:10.1371/journal.pntd.0003017.PubMedPubMedCentralCrossRef

289.

Marciano-Cabral F, Cabral GA. The immune response to Naegleria fowleri amebae and pathogenesis of infection. FEMS Immunol Med Microbiol. 2007;51(2):243–59. doi:10.1111/j.1574-695X.2007.00332.x.PubMedCrossRef

290.

Visvesvara GS, Peralta MJ, Brandt FH, Wilson M, Aloisio C, Franko E. Production of monoclonal antibodies to Naegleria fowleri, agent of primary amebic meningoencephalitis. J Clin Microbiol. 1987;25(9):1629–34.PubMedPubMedCentral

291.

Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol. 2007;50(1):1–26. doi:10.1111/j.1574-695X.2007.00232.x.PubMedCrossRef

292.

Qvarnstrom Y, Visvesvara GS, Sriram R, da Silva AJ. Multiplex real-time PCR assay for simultaneous detection of Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri. J Clin Microbiol. 2006;44(10):3589–95. doi:10.1128/JCM.00875-06.PubMedPubMedCentralCrossRef

293.

Vargas-Zepeda J, Gomez-Alcala AV, Vasquez-Morales JA, Licea-Amaya L, De Jonckheere JF, Lares-Villa F. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin. Arch Med Res. 2005;36(1):83–6.PubMedCrossRef

294.

Seidel JS, Harmatz P, Visvesvara GS, Cohen A, Edwards J, Turner J. Successful treatment of primary amebic meningoencephalitis. N Engl J Med. 1982;306(6):346–8. doi:10.1056/NEJM198202113060607.PubMedCrossRef

295.

Linam WM, Ahmed M, Cope JR, Chu C, Visvesvara GS, da Silva AJ, et al. Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis. Pediatrics. 2015;135(3):e744–8. doi:10.1542/peds.2014-2292.PubMedPubMedCentralCrossRef

296.

Schuster FL, Visvesvara GS. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol. 2004;34(9):1001–27. doi:10.1016/j.ijpara.2004.06.004.PubMedCrossRef

297.

Centers for Disease C, Prevention. Notes from the field: transplant-transmitted Balamuthia mandrillaris—Arizona, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(36):1182.

298.

Centers for Disease C, Prevention. Balamuthia mandrillaris transmitted through organ transplantation—Mississippi, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(36):1165–70.

299.

Farnon EC, Kokko KE, Budge PJ, Mbaeyi C, Lutterloh EC, Qvarnstrom Y, et al. Transmission of Balamuthia mandrillaris by organ transplantation. Clin Infect Dis. 2016;63(7):878–88. doi:10.1093/cid/ciw422.PubMedCrossRef

300.

Bravo FG, Alvarez PJ, Gotuzzo E. Balamuthia mandrillaris infection of the skin and central nervous system: an emerging disease of concern to many specialties in medicine. Curr Opin Infect Dis. 2011;24(2):112–7. doi:10.1097/QCO.0b013e3283428d1e.PubMedCrossRef

301.

Visvesvara GS. Infections with free-living amebae. Handb Clin Neurol. 2013;114:153–68. doi:10.1016/B978-0-444-53490-3.00010-8.PubMedCrossRef

302.

Matin A, Stins M, Kim KS, Khan NA. Balamuthia mandrillaris exhibits metalloprotease activities. FEMS Immunol Med Microbiol. 2006;47(1):83–91. doi:10.1111/j.1574-695X.2006.00065.x.PubMedCrossRef

303.

Kiderlen AF, Radam E, Laube U, Martinez AJ. Resistance to intranasal infection with Balamuthia mandrillaris amebae is T-cell dependent. J Eukaryot Microbiol. 2015;62(1):26–33. doi:10.1111/jeu.12189.PubMedCrossRef

304.

Bravo FG, Seas C. Balamuthia mandrillaris amoebic encephalitis: an emerging parasitic infection. Curr Infect Dis Rep. 2012;14(4):391–6. doi:10.1007/s11908-012-0266-4.PubMedCrossRef

305.

Guarner J, Bartlett J, Shieh WJ, Paddock CD, Visvesvara GS, Zaki SR. Histopathologic spectrum and immunohistochemical diagnosis of amebic meningoencephalitis. Mod Pathol. 2007;20(12):1230–7. doi:10.1038/modpathol.3800973.PubMedCrossRef

306.

Yagi S, Schuster FL, Visvesvara GS. Demonstration of Balamuthia and Acanthamoeba mitochondrial DNA in sectioned archival brain and other tissues by the polymerase chain reaction. Parasitol Res. 2008;102(3):491–7. doi:10.1007/s00436-007-0789-z.PubMedCrossRef

307.

Deetz TR, Sawyer MH, Billman G, Schuster FL, Visvesvara GS. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. Clin Infect Dis. 2003;37(10):1304–12. doi:10.1086/379020.PubMedCrossRef

308.

Cary LC, Maul E, Potter C, Wong P, Nelson PT, Given C 2nd, et al. Balamuthia mandrillaris meningoencephalitis: survival of a pediatric patient. Pediatrics. 2010;125(3):e699–703. doi:10.1542/peds.2009-1797.PubMedCrossRef

309.

Doyle JS, Campbell E, Fuller A, Spelman DW, Cameron R, Malham G, et al. Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. J Neurosurg. 2011;114(2):458–62. doi:10.3171/2010.10.JNS10677.PubMedCrossRef

310.

Orozco L, Hanigan W, Khan M, Fratkin J, Lee M. Neurosurgical intervention in the diagnosis and treatment of Balamuthia mandrillaris encephalitis. J Neurosurg. 2011;115(3):636–40. doi:10.3171/2011.4.JNS102057.PubMedCrossRef

311.

Galarza C, Ramos W, Gutierrez EL, Ronceros G, Teran M, Uribe M, et al. Cutaneous acanthamebiasis infection in immunocompetent and immunocompromised patients. Int J Dermatol. 2009;48(12):1324–9. doi:10.1111/j.1365-4632.2008.03786.x.PubMedCrossRef

312.

Gee SN, Rothschild B, Click J, Sheth V, Saavedra A, Hsu MY. Tender ulceronecrotic nodules in a patient with leukemia. Cutaneous acanthamebiasis. Arch Dermatol. 2011;147(7):857–62. doi:10.1001/archdermatol.2011.162-a.PubMedCrossRef

313.

Dunand VA, Hammer SM, Rossi R, Poulin M, Albrecht MA, Doweiko JP, et al. Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. Clin Infect Dis. 1997;25(2):267–72.PubMedCrossRef

314.

Rivera MA, Padhya TA. Acanthamoeba: a rare primary cause of rhinosinusitis. Laryngoscope. 2002;112(7 Pt 1):1201–3. doi:10.1097/00005537-200207000-00011.PubMedCrossRef

315.

Stehr-Green JK, Bailey TM, Visvesvara GS. The epidemiology of Acanthamoeba keratitis in the United States. Am J Ophthalmol. 1989;107(4):331–6.PubMedCrossRef

316.

Mannis MJ, Tamaru R, Roth AM, Burns M, Thirkill C. Acanthamoeba sclerokeratitis. Determining diagnostic criteria. Arch Ophthalmol. 1986;104(9):1313–7.PubMedCrossRef

317.

Seal DV. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye (Lond). 2003;17(8):893–905. doi:10.1038/sj.eye.6700563.CrossRef

318.

Lim N, Goh D, Bunce C, Xing W, Fraenkel G, Poole TR, et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol. 2008;145(1):130–5. doi:10.1016/j.ajo.2007.08.040.PubMedCrossRef

319.

Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35(8):696–726. doi:10.1007/s10875-015-0201-1.PubMedPubMedCentralCrossRef

320.

Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154–64. doi:10.1182/blood-2015-11-679902.PubMedPubMedCentralCrossRef

321.

Elkaim E, Neven B, Bruneau J, Mitsui-Sekinaka K, Stanislas A, Heurtier L, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210–218 e9. doi:10.1016/j.jaci.2016.03.022.PubMedCrossRef

322.

Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol. 2016; doi:10.1016/j.jaci.2016.06.021.

323.

Engelhardt KR, Gertz ME, Keles S, Schaffer AA, Sigmund EC, Glocker C, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2015;136(2):402–12. doi:10.1016/j.jaci.2014.12.1945.PubMedPubMedCentralCrossRef

324.

Pilmis B, Puel A, Lortholary O, Lanternier F. New clinical phenotypes of fungal infections in special hosts. Clin Microbiol Infect. 2016;22(8):681–7. doi:10.1016/j.cmi.2016.05.016.PubMedCrossRef

325.

Zerbe CS, Marciano BE, Katial RK, Santos CB, Adamo N, Hsu AP, et al. Progressive multifocal leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature. Clin Infect Dis. 2016;62(8):986–94. doi:10.1093/cid/civ1220.PubMedPubMedCentralCrossRef

326.

Jackson CC, Dickson MA, Sadjadi M, Gessain A, Abel L, Jouanguy E, et al. Kaposi sarcoma of childhood: Inborn or acquired immunodeficiency to oncogenic HHV-8. Pediatr Blood Cancer. 2016;63(3):392–7. doi:10.1002/pbc.25779.PubMedCrossRef

327.

Arts P, van de Veerdonk FL, van der Lee R, Langereis MA, Gilissen C, van Zelst-Stams WA, et al. Immunologic defects in severe mucocutaneous HSV-2 infections: response to IFN-gamma therapy. J Allergy Clin Immunol. 2016;138(3):895–8. doi:10.1016/j.jaci.2016.02.025.PubMedCrossRef

328.

Cabral-Marques O, Schimke LF, Pereira PV, Falcai A, de Oliveira JB, Hackett MJ, et al. Expanding the clinical and genetic spectrum of human CD40L deficiency: the occurrence of paracoccidioidomycosis and other unusual infections in Brazilian patients. J Clin Immunol. 2012;32(2):212–20. doi:10.1007/s10875-011-9623-6.PubMedCrossRef

329.

Leven EA, Maffucci P, Ochs HD, Scholl PR, Buckley RH, Fuleihan RL, et al. Hyper IgM syndrome: a report from the USIDNET registry. J Clin Immunol. 2016;36(5):490–501. doi:10.1007/s10875-016-0291-4.PubMedPubMedCentralCrossRef

330.

Recher M, Karjalainen-Lindsberg ML, Lindlof M, Soderlund-Venermo M, Lanzi G, Vaisanen E, et al. Genetic variation in schlafen genes in a patient with a recapitulation of the murine Elektra phenotype. J Allergy Clin Immunol. 2014;133(5):1462–1465, 5 e1–5. doi:10.1016/j.jaci.2013.10.052.PubMedCrossRef

331.

Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol. 2012;130(5):1030–48. doi:10.1016/j.jaci.2012.07.049.PubMedPubMedCentralCrossRef

332.

Casanova JL. Severe infectious diseases of childhood as monogenic inborn errors of immunity. Proc Natl Acad Sci U S A. 2015;112(51):E7128–37. doi:10.1073/pnas.1521651112.PubMedPubMedCentral

333.

Trotta L, Hautala T, Hamalainen S, Syrjanen J, Viskari H, Almusa H, et al. Enrichment of rare variants in population isolates: single AICDA mutation responsible for hyper-IgM syndrome type 2 in Finland. Eur J Hum Genet. 2016;24(10):1473–8. doi:10.1038/ejhg.2016.37.PubMedPubMedCentralCrossRef

334.

Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, Salzer U, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361(18):1727–35. doi:10.1056/NEJMoa0810719.PubMedPubMedCentralCrossRef

335.

Levy R, Okada S, Beziat V, Moriya K, Liu C, Chai LY, et al. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc Natl Acad Sci U S A. 2016;113(51):E8277–E85. doi:10.1073/pnas.1618300114.PubMedPubMedCentralCrossRef

336.

van der Meijden E, Horvath B, Nijland M, de Vries K, Racz E, Diercks GF, et al. Primary polyomavirus infection, not reactivation, as the cause of Trichodysplasia Spinulosa in immunocompromised patients. J Infect Dis. 2016; doi:10.1093/infdis/jiw403.

337.

Lim HK, Seppanen M, Hautala T, Ciancanelli MJ, Itan Y, Lafaille FG, et al. TLR3 deficiency in herpes simplex encephalitis: high allelic heterogeneity and recurrence risk. Neurology. 2014;83(21):1888–97. doi:10.1212/WNL.0000000000000999.PubMedPubMedCentralCrossRef

338.

Chong KW, Lee JH, Choong CT, Paeds MM, Chan DW, Fortier MV, et al. Hemophagocytic lymphohistiocytosis with isolated central nervous system reactivation and optic nerve involvement. J Child Neurol. 2012;27(10):1336–9. doi:10.1177/0883073811435237.PubMedCrossRef

339.

Imashuku S, Iwai A. Isolated central nervous system hemophagocytic lymphohistiocytosis: case report. Neurosurgery. 2006;58(3):E590. doi:10.1227/01.NEU.0000207957.68445.10.PubMedCrossRef

340.

Madkaikar M, Gupta M, Dixit A, Patil V. Predominant neurological manifestations seen in a patient with a biallelic Perforin1 mutation (PRF1; p.R225W). J Pediatr Hematol Oncol. 2016; doi:10.1097/MPH.0000000000000597.

341.

De Flora S, Bonanni P. The prevention of infection-associated cancers. Carcinogenesis. 2011;32(6):787–95. doi:10.1093/carcin/bgr054.PubMedPubMedCentralCrossRef

342.

Crall C, Morley KW, Rabinowits G, Schmidt B, Dioun Broyles A, Huang JT. Merkel cell carcinoma in a patient with GATA2 deficiency: a novel association with primary immunodeficiency. Br J Dermatol. 2016;174(1):169–71. doi:10.1111/bjd.14062.PubMedCrossRef

343.

Ishiji T, Matsumoto K, Kawase M, Nakagawa H. Spontaneous regression of Merkel cell carcinoma developed in a patient with epidermodysplasia verruciformis. J Dermatol. 2014;41(8):759–60. doi:10.1111/1346-8138.12533.PubMedCrossRef

344.

Kwon EK, Halvorson CR, Rady P, Tyring S, Nguyen HP, Kao GF, et al. Merkel cell polyomavirus detection in a patient with familial epidermodysplasia verruciformis. Pediatr Dermatol. 2013;30(4):505–7. doi:10.1111/pde.12130.PubMedCrossRef

345.

Mizuno Y, Kato G, Shu E, Ohnishi H, Fukao T, Ohara O, et al. Merkel cell polyomavirus-positive Merkel cell carcinoma in a patient with epidermodysplasia verruciformis. Acta Derm Venereol. 2015;95(1):98–9. doi:10.2340/00015555-1868.PubMedCrossRef

346.

Oliveira WR, Sotto MN, Festa C, Rady P, Tyring SK. Merkel cell polyomavirus in Merkel cell carcinoma from a Brazilian epidermodysplasia verruciformis patient. J Am Acad Dermatol. 2010;62(5):889–90. doi:10.1016/j.jaad.2009.04.005.PubMedCrossRef

347.

Cohen JI, Dropulic L, Hsu AP, Zerbe CS, Krogmann T, Dowdell K, et al. Association of GATA2 deficiency with severe primary Epstein-Barr Virus (EBV) infection and EBV-associated cancers. Clin Infect Dis. 2016;63(1):41–7. doi:10.1093/cid/ciw160.PubMedPubMedCentralCrossRef

348.

Muehlenbachs A, Bhatnagar J, Agudelo CA, Hidron A, Eberhard ML, Mathison BA, et al. Malignant transformation of Hymenolepis nana in a human host. N Engl J Med. 2015;373(19):1845–52. doi:10.1056/NEJMoa1505892.PubMedCrossRef

349.

Greenberg DE, Porcella SF. Stock F, Wong a, Conville PS, Murray PR et al. Granulibacter bethesdensis gen. nov., sp. nov., a distinctive pathogenic acetic acid bacterium in the family Acetobacteraceae. Int J Syst Evol Microbiol. 2006;56(Pt 11):2609–16. doi:10.1099/ijs.0.64412-0.PubMedCrossRef

350.

Falcone EL, Petts JR, Fasano MB, Ford B, Nauseef WM, Neves JF, et al. Methylotroph infections and chronic granulomatous disease. Emerg Infect Dis. 2016;22(3):404–9. doi:10.3201/eid2203.151265.PubMedPubMedCentralCrossRef

351.

Bloom KA, Chung D, Cunningham-Rundles C. Osteoarticular infectious complications in patients with primary immunodeficiencies. Curr Opin Rheumatol. 2008;20(4):480–5. doi:10.1097/BOR.0b013e3282fd6e70.PubMedPubMedCentralCrossRef

352.

Roifman CM, Rao CP, Lederman HM, Lavi S, Quinn P, Gelfand EW. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med. 1986;80(4):590–4.PubMedCrossRef

353.

Paessler M, Levinson A, Patel JB, Schuster M, Minda M, Nachamkin I. Disseminated Mycoplasma orale infection in a patient with common variable immunodeficiency syndrome. Diagn Microbiol Infect Dis. 2002;44(2):201–4.PubMedCrossRef

354.

Ariganello P, Angelino G, Scarselli A, Salfa I, Della Corte M, De Matteis A, et al. Relapsing campylobacter jejuni systemic infections in a child with X-linked agammaglobulinemia. Case Rep Pediatr. 2013;2013:735108. doi:10.1155/2013/735108.PubMedPubMedCentral

355.

Cuccherini B, Chua K, Gill V, Weir S, Wray B, Stewart D, et al. Bacteremia and skin/bone infections in two patients with X-linked agammaglobulinemia caused by an unusual organism related to Flexispira/Helicobacter species. Clin Immunol. 2000;97(2):121–9. doi:10.1006/clim.2000.4932.PubMedCrossRef

356.

Turvey SE, Leo SH, Boos A, Deans GD, Prendiville J, Crawford RI, et al. Successful approach to treatment of Helicobacter bilis infection in X-linked agammaglobulinemia. J Clin Immunol. 2012;32(6):1404–8. doi:10.1007/s10875-012-9750-8.PubMedCrossRef

357.

Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014;34(8):954–61. doi:10.1007/s10875-014-0102-8.PubMedPubMedCentralCrossRef

358.

Global Health Observatory. 2017. http://apps.who.int/gho/data/node.imr.WHS3_43?lang=en.

359.

Aharonowitz G, Koton S, Segal S, Anis E, Green MS. Epidemiological characteristics of spotted fever in Israel over 26 years. Clin Infect Dis. 1999;29(5):1321–2. doi:10.1086/313432.PubMedCrossRef

360.

Grange JM. Complications of bacille Calmette-Guerin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health. 1998;1(2):84–8.PubMed

Springer Medizin

Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Frauen bekommen seltener eine intensive Statintherapie

Reizdarmsyndrom: Diäten wirksamer als Medikamente

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2017

Severe Enteropathy and Hypogammaglobulinemia Complicating Refractory Mycobacterium tuberculosis Complex Disseminated Disease in a Child with IL-12Rβ1 Deficiency

A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults

Erratum to: Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies

Health-Related Quality of Life and Patients’ Empowerment in the Health Care of Primary Immune Deficiencies

Bialellic Mutations in Tetratricopeptide Repeat Domain 7A (TTC7A) Cause Common Variable Immunodeficiency-Like Phenotype with Enteropathy

Neutropenia in Patients with Common Variable Immunodeficiency: a Rare Event Associated with Severe Outcome